# BioIntelliSense

BioIntelliSense is an other based in Golden, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Golden, United States
- **Region:** North America
- **Address:** Golden, CO, United States
- **Assets under management:** Undisclosed
- **Website:** biointellisense.com
- **LinkedIn:** https://www.linkedin.com/company/biointellisense

## Regulatory record

- **Reports private funds:** No

## About

BioIntelliSense is a continuous health monitoring and clinical intelligence company. The BioButton system delivers scalable continuous monitoring that proactively identifies early signs of patient deterioration. Its wearable continuous monitoring solution collects and analyzes leading indicators of patient decline for in-facility and home use, with BioDashboard exception management software.

## Sectors

- Digital Health
- Medical Devices
- Healthcare Services
- AI/ML

## Questions

### Who leads BioIntelliSense?

BioIntelliSense does not publicly name its CEO or executive team. The company's website and public filings list no individuals in leadership roles. This contrasts with many health-tech firms that highlight founder or executive backgrounds.

### How does BioIntelliSense generate revenue?

BioIntelliSense sells or licenses the BioButton system—hardware, software, and monitoring service—to hospitals, health systems, and post-acute care organizations. The company does not offer direct-to-consumer sales, per its website.

### Does BioIntelliSense have venture capital or other institutional investors?

BioIntelliSense has not disclosed any institutional investors, venture capital rounds, or debt financing. Its ownership structure is unknown. This opacity is unusual for a company marketing clinical-trial-level outcomes.

### What published evidence supports BioIntelliSense's clinical claims?

BioIntelliSense's website cites several peer-reviewed studies, including research from Houston Methodist published in the Journal of Clinical Medicine (Weller et al., 2024) and a before-and-after study in the British Journal of Anaesthesia (Eddahchouri et al., 2022). The company also references internal analyses from American Health Network and Houston Methodist Hospital.

### How does BioIntelliSense's solution differ from standard telemetry or spot-check monitoring?

BioIntelliSense claims that continuous monitoring via the BioButton, compared to intermittent manual vital checks, reduces ICU transfers, rapid response activations, and hospital stays (per studies cited by the company). The system also transitions from in-hospital to home use, a feature not common with traditional telemetry.

## Related profiles

- [Eagle Quest International](https://altss.com/profile/eagle-quest-international)
- [Spore Partners](https://altss.com/profile/spore-partners)

---

Updated: 2026-08-11T15:06:13.093Z

Canonical page: https://altss.com/profile/biointellisense

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology